BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

By WebmasterDecember 9, 2019November 1st, 2024No Comments

Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

See more here

Previous PostiView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis
Next PostHarvard Pilgrim Health Care And Ride Health Collaborate To Provide Health Care-Related Transportation For Medicare Members In Two States

Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostiView Announces First Patient Treated in Phase 2 Clinical Trial Program Evaluating IVIEW-1201 in Patients with Acute Adenoviral Conjunctivitis

Next PostHarvard Pilgrim Health Care And Ride Health Collaborate To Provide Health Care-Related Transportation For Medicare Members In Two States